HRP20140947T1 - Enzimska terapija raka - Google Patents

Enzimska terapija raka Download PDF

Info

Publication number
HRP20140947T1
HRP20140947T1 HRP20140947AT HRP20140947T HRP20140947T1 HR P20140947 T1 HRP20140947 T1 HR P20140947T1 HR P20140947A T HRP20140947A T HR P20140947AT HR P20140947 T HRP20140947 T HR P20140947T HR P20140947 T1 HRP20140947 T1 HR P20140947T1
Authority
HR
Croatia
Prior art keywords
adenosine deaminase
intended
accordance
recombinant
seq
Prior art date
Application number
HRP20140947AT
Other languages
English (en)
Croatian (hr)
Inventor
David R. Filpula
Puja Sapra
Original Assignee
Sigma-Tau Rare Diseases S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Rare Diseases S.A. filed Critical Sigma-Tau Rare Diseases S.A.
Publication of HRP20140947T1 publication Critical patent/HRP20140947T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20140947AT 2007-04-20 2008-04-18 Enzimska terapija raka HRP20140947T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91303907P 2007-04-20 2007-04-20
PCT/US2008/060733 WO2008131163A1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy
EP08754910.1A EP2147122B1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy

Publications (1)

Publication Number Publication Date
HRP20140947T1 true HRP20140947T1 (hr) 2015-02-13

Family

ID=39875909

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140947AT HRP20140947T1 (hr) 2007-04-20 2008-04-18 Enzimska terapija raka

Country Status (19)

Country Link
US (1) US8741283B2 (Direct)
EP (1) EP2147122B1 (Direct)
JP (1) JP5595904B2 (Direct)
KR (1) KR101540296B1 (Direct)
CN (1) CN101680039B (Direct)
BR (1) BRPI0810384B8 (Direct)
CA (1) CA2684749C (Direct)
CY (1) CY1117000T1 (Direct)
DK (1) DK2147122T3 (Direct)
ES (1) ES2507508T3 (Direct)
HR (1) HRP20140947T1 (Direct)
IL (1) IL201593A (Direct)
MX (1) MX2009011320A (Direct)
NZ (1) NZ580980A (Direct)
PL (1) PL2147122T3 (Direct)
PT (1) PT2147122E (Direct)
SI (1) SI2147122T1 (Direct)
TW (1) TWI486169B (Direct)
WO (1) WO2008131163A1 (Direct)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2281888B1 (en) 2004-11-12 2015-01-07 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
KR101499095B1 (ko) 2007-04-20 2015-03-05 시그마-타우 레어 디지즈, 에스.에이. 안정한 재조합 아데노신 데아미나제
WO2012106591A1 (en) * 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
CA2964317C (en) 2014-10-14 2021-10-05 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US10874724B2 (en) * 2015-05-22 2020-12-29 University Of Houston System Enzymatic immunomodulation of solid tumors and uses thereof
CA3056071A1 (en) * 2016-03-11 2017-09-14 University Of Louisville Research Foundation, Inc. Methods and compositions for treating tumors
EP3610000A1 (en) 2017-04-13 2020-02-19 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2020081869A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2023086931A2 (en) * 2021-11-12 2023-05-19 Georgia Tech Research Corporation Adenosine deaminase 1 compositions and methods for using same
US20240250753A1 (en) * 2022-10-10 2024-07-25 Berkeley Marine Robotics Inc. Ship Hull Inspection using a Swarm of Unmanned Underwater Vehicles equipped with Wireless Laser Systems

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346823A (en) 1984-05-29 1994-09-13 Genencor, Inc. Subtilisin modifications to enhance oxidative stability
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6824766B2 (en) 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6251382B1 (en) 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6333396B1 (en) * 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US20020088017A1 (en) * 1999-04-28 2002-07-04 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6579857B1 (en) 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
AU7868400A (en) * 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
WO2002074960A2 (en) * 2000-11-08 2002-09-26 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
AU2002365360A1 (en) 2001-11-28 2003-06-10 Biopolymed Inc. Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US7413738B2 (en) 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20040175804A1 (en) * 2003-03-04 2004-09-09 Skonezny Paul M. Process for preparing dideoxyinosine using adenosine deaminase enzyme
US7301003B2 (en) 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7601798B2 (en) 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US7989554B2 (en) 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
JP2010500963A (ja) 2006-06-21 2010-01-14 エンゾン ファーマスーティカルズ インコーポレイテッド 安定化タンパク質
JP2010503705A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド ヒンダードエステル系の生分解性リンカーを有するポリアルキレンオキサイド
CA2671209A1 (en) 2006-12-29 2008-07-10 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
KR101499095B1 (ko) 2007-04-20 2015-03-05 시그마-타우 레어 디지즈, 에스.에이. 안정한 재조합 아데노신 데아미나제

Also Published As

Publication number Publication date
EP2147122B1 (en) 2014-07-16
CA2684749A1 (en) 2008-10-30
JP5595904B2 (ja) 2014-09-24
US20090047270A1 (en) 2009-02-19
EP2147122A1 (en) 2010-01-27
NZ580980A (en) 2012-04-27
EP2147122A4 (en) 2010-11-17
WO2008131163A8 (en) 2010-01-28
BRPI0810384B8 (pt) 2021-05-25
BRPI0810384B1 (pt) 2021-02-02
ES2507508T3 (es) 2014-10-15
KR20090130108A (ko) 2009-12-17
US8741283B2 (en) 2014-06-03
PT2147122E (pt) 2014-10-15
BRPI0810384A2 (pt) 2014-11-04
CA2684749C (en) 2016-06-21
PL2147122T3 (pl) 2015-05-29
SI2147122T1 (sl) 2015-01-30
RU2009142817A (ru) 2011-05-27
KR101540296B1 (ko) 2015-07-31
CY1117000T1 (el) 2017-04-05
AU2008242791A1 (en) 2008-10-30
IL201593A0 (en) 2010-05-31
CN101680039B (zh) 2016-08-24
MX2009011320A (es) 2009-12-15
IL201593A (en) 2017-07-31
WO2008131163A1 (en) 2008-10-30
TWI486169B (zh) 2015-06-01
TW200902051A (en) 2009-01-16
JP2010524968A (ja) 2010-07-22
DK2147122T3 (da) 2014-10-13
CN101680039A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
HRP20140947T1 (hr) Enzimska terapija raka
Veiman et al. PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo
Li et al. A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression
ES2661461T3 (es) Polímeros de polioxazolina y métodos para su preparación, conjugados de estos polímeros, y sus usos médicos
Karuppusamy et al. Nanoengineered chlorin e6 conjugated with hydrogel for photodynamic therapy on cancer
Larson et al. Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer–drug conjugates and gold nanorod induced hyperthermia
JP2010524968A5 (Direct)
Qiu et al. A self-delivery membrane system for enhanced anti-tumor therapy
Zhang et al. Folate-conjugated polyspermine for lung cancer–targeted gene therapy
Kasala et al. Utilizing adenovirus vectors for gene delivery in cancer
ATE545699T1 (de) Modifizierte, rekombinante vacciniaviren und deren verwendungen
WO2010033220A3 (en) Modified therapeutics peptides, methods of their preparation and use
BRPI0417213A (pt) tratamento de gliomas malìgnos com inibidores de tgf-beta
Chen et al. Fabrication of dual responsive co-delivery system based on three-armed peptides for tumor therapy
JP2017513516A5 (Direct)
Oh et al. Electrostatic charge conversion processes in engineered tumor-identifying polypeptides for targeted chemotherapy
BR112012013139A2 (pt) oligopeptídeos imp-3 e vacinas incluindo os mesmos
WO2007070372A3 (en) Compositions and methods for inhibiting cellular proliferation
Zaiden et al. Inhibition of CD44v3 and CD44v6 function blocks tumor invasion and metastatic colonization
Choi et al. Hyaluronate dots for highly efficient photodynamic therapy
Tang et al. Innovative theranostic hydrogels for targeted gastrointestinal cancer treatment
US20190142953A1 (en) Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
Noh et al. Preparation of iron oxide nanoparticles functionalized with Y-shaped ligands for brain tumor targeting
CN101353647B (zh) 靶向肿瘤的模拟逆转录病毒及其制备方法和应用
Ku et al. pH-Responsive globular poly (ethylene glycol) for photodynamic tumor therapy